ELTX Stock Analysis: Buy, Sell, or Hold?
ELTX - Elicio Therapeutics, Inc. Common Stock
$4.09
-10.77 (-72.49%)
▼
5d:
-69.85%
30d:
-62.52%
90d:
-66.41%
WAIT
LOW Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When ELTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ELTX is down 69.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ELTX is down 69.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ELTX is currently trading at $4.08, which is considered oversold relative to its 30-day fair value range of $9.12 to $13.45.
Technical Outlook: Technically, ELTX is in a uptrend. The price is currently testing key support at $10.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 72.5% recently.
Market Sentiment: ELTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.67 (+39.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ELTX is in a uptrend. The price is currently testing key support at $10.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 72.5% recently.
Market Sentiment: ELTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $20.67 (+39.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.12 -
$13.45
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-72.5%)
- BULLISH: Trading 39.2% below Wall St target ($20.67)
- WARNING: Recommendation downgraded due to -69.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$9.12 -
$13.45
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.09
Resistance Level
$14.97
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.24
Wall Street Target
$20.67
(+39.2%)
Share & Embed Analysis
Last updated: June 15, 2026 1:22 PM ET
Data refreshes hourly during market hours. Next update: 2:22 PM
Data refreshes hourly during market hours. Next update: 2:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
